Michael Makris/LinkedIn
Oct 30, 2025, 03:53
Michael Makris on Biomarin’s Decision to Divest Roctavian
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Biomarin, the only manufacturer of an approved hemophilia A gene therapy has decided to divest Roctavian and remove it from their portfolio.
They plan to sell it on to a more established hemophilia company, if they can find a buyer.
The problems have been the high cost and limited durability.
This is a sad turn of events but not surprising to anybody who follows the field.
We suspected that sales were poor, but not this poor, as indicated in their press release.
This is their press release.”
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List